Related Experiment Video
Updated: Feb 14, 2026

Visualizing Antigen Specific CD4+ T Cells using MHC Class II Tetramers
Published on: March 6, 2009
Flow Cytometric Clinical Immunomonitoring Using Peptide-MHC Class II Tetramers: Optimization of Methods and Protocol
Diahann T S L Jansen1, Nishta Ramnoruth1, Khai L Loh2
1University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Insights
Antigen-specific CD4+ T cell monitoring is crucial for new autoimmune therapies. This study presents a robust flow cytometry assay using peptide-MHC class II (pMHCII) multimers for standardized immune monitoring of CD4+ T cells ex vivo.
Area of Science:
- Immunology
- Cellular Immunology
- Clinical Trials
Background:
- Novel immunotherapies aim to induce tolerance in autoimmune diseases.
- Monitoring antigen-specific CD4+ T cell responses is vital for assessing treatment efficacy in early trials.
- Peptide-MHC class II (pMHCII) multimers offer a method for ex vivo analysis of CD4+ T cell populations.
Purpose of the Study:
- To compare existing protocols and reagents for pMHCII multimer assays.
- To identify sources of variability in tetramer binding assays.
- To establish a standardized, robust flow cytometry assay for quantifying and phenotyping antigen-specific CD4+ T cells.
Main Methods:
- Methodological analysis comparing published protocols for pMHCII multimer assays.
- Testing of available reagents to identify limitations.
- Development and description of a robust pMHCII flow cytometry-based assay.
- Utilized frozen peripheral blood mononuclear cell (PBMC) samples for ex vivo analysis.
Main Results:
- Identified reagent and assay limitations hindering global application of pMHCII multimer assays.
- Characterized sources of variability in tetramer binding assays.
- Developed a robust flow cytometry assay for ex vivo quantification and phenotyping of antigen-specific CD4+ T cells.
Conclusions:
- A standardized pMHCII flow cytometry assay is needed for reliable immune monitoring in clinical trials.
- The described assay provides a robust method for analyzing antigen-specific CD4+ T cells ex vivo.
- Further cross-laboratory testing is recommended to standardize immune-monitoring results.
Abstract:
With the advent of novel strategies to induce tolerance in autoimmune and autoimmune-like conditions, clinical trials of antigen-specific tolerizing immunotherapy have become a reality. Besides safety, it will be essential to gather mechanistic data on responding CD4+ T cells to assess the effects of various immunomodulatory approaches in early-phase trials. Peptide-MHC class II (pMHCII) multimers are an ideal tool for monitoring antigen-specific CD4+ T cell responses in unmanipulated cells directly ex vivo. Various protocols have been published but there are reagent and assay limitations across laboratories that could hinder their global application to immune monitoring. In this methodological analysis, we compare protocols and test available reagents to identify sources of variability and to determine the limitations of the tetramer binding assay. We describe a robust pMHCII flow cytometry-based assay to quantify and phenotype antigen-specific CD4+ T cells directly ex vivo from frozen peripheral blood mononuclear cell samples, which we suggest should be tested across various laboratories to standardize immune-monitoring results.
More Related Videos
06:25Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining
Published on: December 23, 2016
09:32Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
Published on: October 15, 2021
Related Concept Videos
Peptide Bonds
Development of Analytical Methods
Drug Classes and Categories
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Optimal Foraging
Clinically Relevant Drug Product Specifications: Methods of Establishment